Phase II Randomized Double Blind Clinical Trial Three Preventive Vaccine Formulations Consisting of Autologous Dendritic Cells and Lymphocytes Incubated With Different Quantities of Spike Protein Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), in Subjects Not Proven Actively Infected or Never Infected With COVID-19
Latest Information Update: 31 Aug 2022
At a glance
- Drugs AV-COVID-19 (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Sponsors AiVita Biomedical
- 29 Aug 2022 According to an Aivita Biomedical media release, results from the study were published in in the journal Human Vaccines & Immunotherapeutics.
- 29 Aug 2022 Results presented in an Aivita Biomedical media release.
- 23 Aug 2021 New trial record